OverviewSuggest Edit

Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. It provides an antisense technology platform designed to treat complicated and rare diseases. The company offers SPINRAZA, a treatment for children and adults with spinal muscular atrophy (SMA), TEGSEDI, a medicine that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, and Waylivra, a medicine used to treat familial chylomicronaemia syndrome (FCS).
TypePublic
Founded1989
HQCarlsbad, CA, US
Websiteionispharma.com
Employee Ratings3.7
Overall CultureD-

Latest Updates

Employees (est.) (Feb 2021)757(-7%)
Job Openings53
Revenue (FY, 2020)$729.3 M(-35%)
Share Price (May 2022)$36.9
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Ionis Pharmaceuticals

Brett P. Monia

Brett P. Monia

Chief Executive Officer, Director
Onaiza Cadoret-Manier

Onaiza Cadoret-Manier

Executive Vice President, Chief Product Strategy and Operations Officer
C. Frank Bennett

C. Frank Bennett

Executive Vice President, Chief Scientific Officer
Eric E. Swayze

Eric E. Swayze

Executive Vice President, Research
Richard S. Geary

Richard S. Geary

Executive Vice President, Chief Development Officer
Patrick R. O'Neil

Patrick R. O'Neil

Chief Legal Officer and General Counsel
Show more

Ionis Pharmaceuticals Office Locations

Ionis Pharmaceuticals has an office in Carlsbad
Carlsbad, CA, US (HQ)
2855 Gazelle Ct
Show all (1)

Ionis Pharmaceuticals Financials and Metrics

Ionis Pharmaceuticals Revenue

Embed Graph
View revenue for all periods
Ionis Pharmaceuticals's revenue was reported to be $729.26 m in FY, 2020 which is a 35% decrease from the previous period.
USD

Revenue (Q1, 2021)

111.6m

Gross profit (Q1, 2021)

109.0m

Gross profit margin (Q1, 2021), %

97.7%

Net income (Q1, 2021)

(89.9m)

EBIT (Q1, 2021)

(92.0m)

Market capitalization (25-May-2022)

5.3b

Closing stock price (25-May-2022)

36.9

Cash (31-Mar-2021)

414.2m

EV

5.0b
Ionis Pharmaceuticals's current market capitalization is $5.3 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

599.7m1.1b729.3m

Revenue growth, %

87%(35%)

Cost of goods sold

1.8m4.4m11.9m

Gross profit

597.9m1.1b717.3m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

297.2m163.8m167.9m133.4m145.5m160.1m111.6m

Cost of goods sold

1.0m1.4m967.0k2.5m3.0m3.1m2.6m

Gross profit

296.2m162.4m166.9m130.8m142.5m157.0m109.0m

Gross profit Margin, %

100%99%99%98%98%98%98%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

278.8m683.3m397.7m

Accounts Receivable

12.8m63.0m76.2m

Inventories

8.6m18.2m22.0m

Current Assets

2.2b2.7b2.1b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

375.8m272.5m247.9m486.2m530.2m633.1m414.2m

Accounts Receivable

10.5m31.6m49.1m28.6m27.8m39.0m23.4m

Inventories

11.1m18.5m19.4m22.9m23.7m22.2m22.2m

Current Assets

2.4b2.4b2.4b2.6b2.5b2.5b2.0b
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

215.0m303.3m(486.8m)

Depreciation and Amortization

12.5m16.0m17.2m

Inventories

1.4m(5.4m)(1.3m)

Accounts Payable

(655.0k)(16.3m)(2.8m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

90.9m80.9m99.3m(58.5m)(102.2m)(145.3m)(89.9m)

Depreciation and Amortization

3.5m8.2m11.9m4.1m7.4m12.6m4.9m

Inventories

(2.5m)(5.7m)(6.6m)(2.2m)(3.0m)(1.5m)(234.0k)

Accounts Payable

(17.2m)(16.1m)(18.8m)411.0k(14.9m)(11.0m)(9.6m)
USDFY, 2018

Revenue/Employee

1.1m

Debt/Equity

0.5 x

Debt/Assets

0.2 x

Financial Leverage

2.2 x
Show all financial metrics

Ionis Pharmaceuticals Operating Metrics

FY, 2018FY, 2019FY, 2020Jun, 2021

Patents (US)

161

Phase I Trials Products

746

Phase II Trials Products

141724

Phase III Trials Products

356
Show all operating metrics

Ionis Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
Akcea TherapeuticsAugust 31, 2020$500 m
Akcea Securities Corporation
Akcea Therapeutics Canada Inc
Akcea Therapeutics France SAS
Akcea Therapeutics Germany GmbH
Akcea Therapeutics, Inc
Akcea Therapeutics Ireland Limited
Akcea Therapeutics UK Limited
Ionis Development (Ireland) Limited
Isis USA Limited
Show more

Ionis Pharmaceuticals Revenue Breakdown

Embed Graph

Ionis Pharmaceuticals revenue breakdown by business segment: 19.6% from Akcea Therapeutics and 80.4% from Ionis Core

Ionis Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Ionis Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Ionis Pharmaceuticals Online and Social Media Presence

Embed Graph

Ionis Pharmaceuticals Company Culture

  • Overall Culture

    D-

    56/100

  • CEO Rating

    F

    53/100

  • Compensation

    C-

    62/100

  • Diversity

    D

    60/100

Learn more on Comparably

Ionis Pharmaceuticals News and Updates

Global RNAi Therapeutics Market Research Report 2022: A Concentrated Market - Key Players are Moderna, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Silence Therapeutics

DUBLIN, April 7, 2022 /PRNewswire/ -- The "Global RNAi Therapeutics Market: Analysis By Molecule Type, By Application, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2026" report has been added to ResearchAndMarkets.com's offering. The report provides an in-depth...

What’s Next For Ionis Pharmaceuticals Stock After A 14% Fall?

The stock price of Ionis Pharmaceuticals, a biotech company that specializes in discovering and developing RNA-targeted therapeutics, plunged 14% in yesterday’s trade to its five year low levels of $30, while it is down 19% over the last one month...

Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (NASDAQ: BCYC) to increase the delivery capabilities of Ionis' advanced LIgand Conjugated Antisense (LICA) medicines.

Ionis Pharmaceuticals Stock Looks Attractive At $37

We believe that the stock price of Ionis Pharmaceuticals, a biotech company that specializes in discovering and developing RNA-targeted therapeutics, is undervalued at current levels of under $37. IONS stock is down 11% from the levels of around $42 it was at on March 23, 2020...

Ionis Pharmaceuticals (IONS) Names Joseph Loscalzo Chairman, Allene Diaz Appointed Director

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced changes to its board of directors. Joseph Loscalzo, M.D., Ph.D., has been appointed chairman of the board and Allene M. Diaz has been appointed to the board.

SVB Leerink Boosts Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $41.00

Ionis Pharmaceuticals (NASDAQ:IONS) had its target price lifted by equities researchers at SVB Leerink from $36.00 to $41.00 in a research note issued on Friday, Benzinga reports. The firm currently has a "market perform" rating on the stock. SVB Leerink's target price points to a potential upside o…
Show more

Ionis Pharmaceuticals Blogs

Ionis to present at RBC Capital Markets Global Healthcare Conference

CARLSBAD, Calif. , May 12, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022 .     A live webcast and additional information about this presentation can be

Ionis to host 2022 virtual Annual Meeting of Stockholders

CARLSBAD, Calif. , May 2, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2022 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 2, 2022 .     The agenda for the event is as follows: -

Ionis to hold first quarter 2022 financial results webcast

Ionis to hold first quarter 2022 financial results webcast Content Import Wed, 04/20/2022 - 07:07 Ionis to hold first quarter 2022 financial results webcast April 20, 2022 at 7:05 AM EDT General Webcast scheduled for Wednesday, May 4 at 11:30 a.m. …

Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session

Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session william.meady@… Mon, 04/04/2022 - 00:16 Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at…

Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine

Treatment with donidalorsen in Phase 2 study significantly reduced angioedema attacks by 90% and provided improvement in quality of life Published findings demonstrate favorable safety and tolerability profile of donidalorsen in Phase 2 study Donidalorsen is one of Ionis’ wholly owned medicines the

Ionis calls for applications for Janice Wiesman Young Investigator Grant Program

- $50,000 grant will fund research and understanding of transthyretin amyloidosis CARLSBAD, Calif. , March 7, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced it is now accepting applications for the Janice Wiesman Young Investigator Grant Program , which honors
Show more

Ionis Pharmaceuticals Frequently Asked Questions

  • When was Ionis Pharmaceuticals founded?

    Ionis Pharmaceuticals was founded in 1989.

  • Who are Ionis Pharmaceuticals key executives?

    Ionis Pharmaceuticals's key executives are Brett P. Monia, Onaiza Cadoret-Manier and C. Frank Bennett.

  • How many employees does Ionis Pharmaceuticals have?

    Ionis Pharmaceuticals has 757 employees.

  • What is Ionis Pharmaceuticals revenue?

    Latest Ionis Pharmaceuticals annual revenue is $729.3 m.

  • What is Ionis Pharmaceuticals revenue per employee?

    Latest Ionis Pharmaceuticals revenue per employee is $963.4 k.

  • Who are Ionis Pharmaceuticals competitors?

    Competitors of Ionis Pharmaceuticals include Lannett, Intellia Therapeutics and Ultragenyx Pharmaceutical.

  • Where is Ionis Pharmaceuticals headquarters?

    Ionis Pharmaceuticals headquarters is located at 2855 Gazelle Ct, Carlsbad.

  • Where are Ionis Pharmaceuticals offices?

    Ionis Pharmaceuticals has an office in Carlsbad.

  • How many offices does Ionis Pharmaceuticals have?

    Ionis Pharmaceuticals has 1 office.